BioSpace News Archive

NEXGEL, Inc. today announced that it will report its financial and operating results for the second quarter of 2022 after the market closes on August 10, 2022.

Mind Medicine today announced that it will host its earnings call on Thursday, August 11, 2022 , at 4:30 p.m. EDT to discuss its financial results for the quarter ended June 30, 2022.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, August 11, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a corporate update.

Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that the Company’s Management will participate virtually in the Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022.

Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53.

Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, announced that the Company will release financial results for the second quarter ended June 30, 2022 on Wednesday, August 10, 2022, after the markets close.

Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.

Galmed Pharmaceuticals Ltd. provides today a business update and reports financial results for the three and six months ended June 30, 2022.

Biostage, Inc.today announced that it will release Q2 2022 financial results on August 4, 2022 and host a conference call and webcast on August 5, 2022 at 9:00 AM ET to discuss financial results and business updates for the second-quarter 2022.

Astria Therapeutics, Inc. today announced initiation of a Phase 1a clinical trial of STAR-0215 in healthy subjects.